The new guidelines offer conditional recommendations for the long-term use of specific GLP-1 therapies—namely liraglutide, semaglutide, and tirzepatide—in treating adults with obesity (defined as a Body Mass Index, or BMI, of 30 or higher). Representational image
World
N
News18 English•03/12/2025

WHO Unveils Landmark GLP-1 Guidelines, Urges Global Action for Safe, Equitable Obesity Treatment

  • •WHO releases first global guidelines on GLP-1 receptor agonist therapies for obesity treatment.
  • •GLP-1 drugs like semaglutide and tirzepatide are recommended for long-term use in adults with a BMI of 30 or higher.
  • •WHO emphasizes that GLP-1 therapies must be combined with intensive behavioral interventions for effective obesity management.
  • •Concerns over cost, equity, and safety of GLP-1 drugs highlighted, with calls for global cooperation to improve access and affordability.
  • •WHO warns of potential side effects and the risk of falsified GLP-1 products due to high demand.

Why it matters: The WHO guidelines could transform global obesity care and drive urgent action on access and safety.

Read Full Article on News18 in English
✦

Related Articles

Loading more articles...